Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS
Neha J. Pagidipati(Alnylam Pharmaceuticals (United States)), Eric D. Peterson(Duke University), Jennifer B. Green, Helena W. Rodbard, Svati H. Shah(Duke University), Rury R. Holman(Chinese University of Hong Kong), Robert J. Mentz, Darren K. McGuire, Cynthia M. Westerhout(Canadian VIGOUR Centre), Pablo Aschner(Hospital Universitario San Ignacio), Yinggan Zheng(Canadian VIGOUR Centre), Tuncay Delibaşı(Hacettepe University)
Cited by 77
Related Papers
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
|Circulation|2020|9.4k
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
|Circulation|2019|9.1k
Heart Disease and Stroke Statistics—2018 Update: A Report From the American Heart Association
|Circulation|2018|7.2k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Heart Disease and Stroke Statistics—2021 Update
|Circulation|2021|5.7k